Journal of Hepatology
Volume 44, Issue 1 , Pages 23-26 , January 2006

What is the current treatment of PTLD after liver transplantation?

  • Jean-François Dufour

      Affiliations

    • Department of Clinical Pharmacology, University of Bern, Murtenstrasse 35, 3010 Bern, Switzerland
    • Corresponding Author InformationCorresponding author. Tel.: +41 31 632 3191; fax: +41 31 632 4997.
    • ,
  • Martin F. Fey

      Affiliations

    • Department of Medical Oncology, Inselspital, Bern, Switzerland

References 

  1. Leblond V, Choquet S. Lymphoproliferative disorders after liver transplantation. J Hepatol. 2004;40:728–735
  2. Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71:1076–1088
  3. Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Pediatr Transplant. 2004;8:267–272
  4. Smets F, Sokal EM. Epstein–Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management. Pediatr Transplant. 2002;6:280–287
  5. Serinet MO, Jacquemin E, Habes D, Debray D, Fabre M, Bernard O. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein–Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr. 2002;34:389–393
  6. Nathanson S, Debray D, Delarue A, Deschenes G. Long-term survival after post-transplant lymphoproliferative disease in children. Pediatr Nephrol. 2002;17:668–672
  7. Venzke A, Ganschow R, Grabhorn E, Rogiers X, Burdelski M. Basiliximab monotherapy following B-cell lymphoma after pediatric liver transplantation and anti-CD20 therapy. Pediatr Transplant. 2003;7:404–407
  8. Jimenez-Rivera C, Avitzur Y, Fecteau AH, Jones N, Grant D, Ng VL. Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant. 2004;8:243–248
  9. Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients. J Pediatr Gastroenterol Nutr. 2004;38:198–203
  10. Kogan-Liberman D, Burroughs M, Emre S, Moscona A, Shneider BL. The role of quantitative Epstein–Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience. J Pediatr Gastroenterol Nutr. 2001;33:445–449
  11. Barshes NR, Lee TC, Karpen SJ, Bristow LJ, Quiros-Tejeira RE, Goss JA. Asymptomatic small bowel intussusception associated with post-transplant lymphoproliferative disease. Pediatr Transplant. 2004;8:196–197
  12. Baron PW, Heneghan MA, Suhocki PV, Nuckols JD, Tuttle-Newhall JE, Howell DN, et al. Biliary stricture secondary to donor B-cell lymphoma after orthotopic liver transplantation. Liver Transpl. 2001;7:62–67
  13. Koffman BH, Kennedy AS, Heyman M, Colonna J, Howell C. Use of radiation therapy in posttransplant lymphoproliferative disorder (PTLD) after liver transplantation. Int J Cancer. 2000;90:104–109
  14. Castellano-Sanchez AA, Li S, Qian J, Lagoo A, Weir E, Brat DJ. Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol. 2004;121:246–253
  15. Mentzer SJ, Perrine SP, Faller DV. Epstein–Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl Infect Dis. 2001;3:177–185
  16. Oertel SH, Anagnostopoulos I, Hummel MW, Jonas S, Riess HB. Identification of early antigen BZLF1/ZEBRA protein of Epstein–Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease. Br J Haematol. 2002;118:1120–1123
  17. McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation. 1998;66:1604–1611
  18. Davis CL, Wood BL, Sabath DE, Joseph JS, Stehman-Breen C, Broudy VC. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation. 1998;66:1770–1779
  19. Gerstenkorn C, Jackson G, Di Franco F, Thomusch O, Talbot D. Outcome of PTLD in renal and liver allograft recipients. Transplant Proc. 2001;33:2469–2472
  20. Borges E, Ferry JA, Friedmann AM. Epstein–Barr virus-negative precursor B cell lymphoblastic lymphoma after liver transplantation: a unique form of posttransplant lymphoproliferative disease. Transplantation. 2002;73:541–543
  21. Zompi S, Tulliez M, Conti F, Leblond V, Gaulard P, Blanche P, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases. J Hepatol. 2000;32:521–527
  22. Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26:66–73
  23. Ganne V, Siddiqi N, Kamaplath B, Chang CC, Cohen EP, Bresnahan BA, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant. 2003;17:417–422
  24. Dotti G, Rambaldi A, Fiocchi R, Motta T, Torre G, Viero P, et al. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. Haematologica. 2001;86:618–623
  25. Berney T, Delis S, Kato T, Nishida S, Mittal NK, Madariaga J, et al. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Transplantation. 2002;74:1000–1006
  26. Haque T, Amlot PL, Helling N, Thomas JA, Sweny P, Rolles K, et al. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol. 1998;160:6204–6209
  27. Khanna R, Bell S, Sherritt M, Galbraith A, Burrows SR, Rafter L, et al. Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA. 1999;96:10391–10396
  28. Haque T, Taylor C, Wilkie GM, Murad P, Amlot PL, Beath S, et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation. 2001;72:1399–1402
  29. Comoli P, Labirio M, Basso S, Baldanti F, Grossi P, Furione M, et al. Infusion of autologous Epstein–Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood. 2002;99:2592–2598
  30. Green M, Reyes J, Webber S, Rowe D. The role of antiviral and immunoglobulin therapy in the prevention of Epstein–Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl Infect Dis. 2001;3:97–103
  31. Haddad E, Paczesny S, Leblond V, Seigneurin JM, Stern M, Achkar A, et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1–2 clinical trial. Blood. 2001;97:1590–1597
  32. Yedibela S, Reck T, Niedobitek G, Gramatzki M, Repp R, Hohenberger W, et al. Anti-CD20 monoclonal antibody treatment of Epstein–Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation. Transpl Int. 2003;16:197–201
  33. Marom EM, McAdams HP, Butnor KJ, Coleman RE. Positron emission tomography with fluoro-2-deoxy-d-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients. J Thorac Imaging. 2004;19:74–78

PII: S0168-8278(05)00675-6

doi: 10.1016/j.jhep.2005.10.009

Journal of Hepatology
Volume 44, Issue 1 , Pages 23-26 , January 2006

Article Tools